Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

A Comparison Of Global Blood Therapeutics' GBT440 And bluebird bio's LentiGlobin Apr. 07, 2017 4:14 PM ET Pfizer Inc. (PFE) Stock AES, BLUE, SCD PFE 11 Comments Emerging Equities 1.35K Follower s ...

For Q1 2018 (ended on March 31), Global Blood Therapeutics posted $41.6M ($0.87 per share) net losses compared to $23.3M ($0.60 per share) declines (for the same period a year prior).

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic. Pfizer said ...

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced the presentation of a case study highlighting the effect of GBT440 ...

Dr. Ted Love leads Global Blood Therapeutics against sickle cell expand Dr. Ted Love CEO, Global Blood Therapeutics Inc. Paolo Vescia By Ron Leuty – Senior Reporter, San Francisco Business Times ...

* Global Blood Therapeutics Inc - ‍qtrly cash, cash equivalents, marketable securities $259.4 million at Sept 30, 2017 versus $197.3 million at Dec 31, 2016 Source text for Eikon: Further ...

Aug 7 (Reuters) - Global Blood Therapeutics Inc * Global Blood Therapeutics reports recent business progress and provides second quarter 2017 financial results * Q2 loss per share $0.55 ...

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2018 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT), a clinical-stage biopharmaceutical company determined to discover, develop and ...